These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 9309147

  • 1. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K.
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
    [Abstract] [Full Text] [Related]

  • 2. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K, Nagasu T.
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
    [Abstract] [Full Text] [Related]

  • 3. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 6. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA, Chen Z, Diehl RE, Conner MW, Chen HY, Trumbauer ME, Gopal-Truter S, Seeburger G, Bhimnathwala H, Abrams MT, Davide JP, Ellis MS, Gibbs JB, Greenberg I, Koblan KS, Kral AM, Liu D, Lobell RB, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Senderak ET, Oliff A, Kohl NE.
    Cancer Res; 2000 May 15; 60(10):2680-8. PubMed ID: 10825141
    [Abstract] [Full Text] [Related]

  • 7. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.
    Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM.
    Cancer Res; 1995 Nov 15; 55(22):5310-4. PubMed ID: 7585593
    [Abstract] [Full Text] [Related]

  • 9. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, Patel DV, Patel MM, Schmidt RJ, Weller HN, Andahazy ML, Carboni JM, Gullo-Brown JL, Lee FY, Ricca C, Rose WC, Yan N, Barbacid M, Hunt JT, Meyers CA, Seizinger BR, Zahler R, Manne V.
    J Med Chem; 1996 Jan 05; 39(1):224-36. PubMed ID: 8568812
    [Abstract] [Full Text] [Related]

  • 10. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V, Yan N, Carboni JM, Tuomari AV, Ricca CS, Brown JG, Andahazy ML, Schmidt RJ, Patel D, Zahler R.
    Oncogene; 1995 May 04; 10(9):1763-79. PubMed ID: 7753553
    [Abstract] [Full Text] [Related]

  • 11. Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
    Agarwal R, Mohan RR, Ahmad N, Mukhtar H.
    Mol Carcinog; 1996 Sep 04; 17(1):13-22. PubMed ID: 8876671
    [Abstract] [Full Text] [Related]

  • 12. [Inhibitors of Ras farnesylation: tomorrow's anticancer agents?].
    Perrin D, Halazy S, Hill B.
    Bull Cancer; 1997 Jun 04; 84(6):635-42. PubMed ID: 9295868
    [Abstract] [Full Text] [Related]

  • 13. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
    Qian Y, Vogt A, Sebti SM, Hamilton AD.
    J Med Chem; 1996 Jan 05; 39(1):217-23. PubMed ID: 8568811
    [Abstract] [Full Text] [Related]

  • 14. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Cancer Res; 1995 Oct 01; 55(19):4243-7. PubMed ID: 7671229
    [Abstract] [Full Text] [Related]

  • 15. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA, Sigman CC.
    Cancer Epidemiol Biomarkers Prev; 1997 Apr 01; 6(4):267-82. PubMed ID: 9107432
    [Abstract] [Full Text] [Related]

  • 16. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 17. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
    Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM.
    Cancer Res; 2003 Dec 15; 63(24):8922-9. PubMed ID: 14695209
    [Abstract] [Full Text] [Related]

  • 18. Farnesyltransferase as a target for anticancer drug design.
    Qian Y, Sebti SM, Hamilton AD.
    Biopolymers; 1997 Dec 15; 43(1):25-41. PubMed ID: 9174410
    [Abstract] [Full Text] [Related]

  • 19. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
    Aklilu F, Park M, Goltzman D, Rabbani SA.
    Cancer Res; 1997 Oct 15; 57(20):4517-22. PubMed ID: 9377563
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC, Hamilton AD, Sebti SM.
    Anticancer Drug Des; 1997 Jun 15; 12(4):229-38. PubMed ID: 9199657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.